Previous 10 | Next 10 |
home / stock / mrna / mrna articles
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and affo...
Surprisingly, it is not Big Tech that kicked off 2024 but healtchare champions. Moderna Inc (NASDAQ: MRNA) shares rose after Oppenheimer ...
Around 15% of Americans said they were planning to participate this year in Dry January — a month of abstinence from alcohol — according to a s...
The negative sentiment observed in the stock market at the beginning of the year appears to persist, with index futures pointing to a lower opening...
U.S. stocks experienced mixed results in Tuesday’s trading session. The Dow Jones index showed resilience, gaining around 25 points, a modest...
Shares of Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) rose sharply during Tuesday’s session after the company released topline data from...
Pfizer, Inc. (NYSE: PFE) shares are trading higher on the first trading day of 2024 after the stock lost more than 40% in 2023. Here's a look a...
Moderna Inc (NASDAQ: MRNA) shares are trading higher Tuesday following positive analyst coverage from Oppenheimer. What Happened: Oppenhe...
During the last week of 2023, AstraZeneca PLC (NASDAQ: AZN) agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc. as...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...